CalciMedica, Inc. (NASDAQ:CALC) Director Purchases $27,270.89 in Stock

CalciMedica, Inc. (NASDAQ:CALC) Director Robert N. Wilson purchased 8,443 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were purchased at an average cost of $3.23 per share, for a total transaction of $27,270.89. Following the completion of the purchase, the director now directly owns 258,918 shares in the company, valued at $836,305.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

CalciMedica Price Performance

CALC opened at $4.26 on Thursday. The company’s 50 day simple moving average is $5.23 and its 200 day simple moving average is $4.63. CalciMedica, Inc. has a 1 year low of $1.75 and a 1 year high of $8.38.

CalciMedica (NASDAQ:CALC) last released its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. As a group, sell-side analysts anticipate that CalciMedica, Inc. will post -2.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CalciMedica

Several hedge funds have recently modified their holdings of CALC. Hudson Bay Capital Management LP acquired a new stake in shares of CalciMedica in the third quarter worth approximately $432,000. BML Capital Management LLC boosted its position in shares of CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock worth $416,000 after acquiring an additional 56,643 shares during the last quarter. Finally, Meritage Portfolio Management raised its holdings in CalciMedica by 360.0% in the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock valued at $132,000 after buying an additional 36,000 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CALC shares. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of CalciMedica in a research note on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of CalciMedica in a research note on Thursday, June 27th. Finally, Singular Research raised shares of CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.